Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) has announced its upcoming participation in several major investor conferences, showcasing its commitment to engaging with institutional investors and sharing company developments.
Key conference appearances include:
- Chardan Capital Conference (April 29, 2025) - CEO David Hochman will join a virtual fireside chat at 10:30am ET discussing "Data & Regulatory Catalysts"
- Jefferies Global Healthcare Conference (June 5, 2025) - Management team will conduct a live fireside chat at 3:45pm ET in New York
- H.C. Wainwright BioConnect Conference (May 20, 2025) - Company will deliver a presentation and host one-on-one investor meetings
All virtual events will be accessible through live webcasts and will remain available on Orchestra BioMed's Investor Relations website after the events. The company, which focuses on accelerating high-impact technologies through risk-reward sharing partnerships, will also offer one-on-one meetings with investors at selected conferences.
Positive
- Multiple high-profile investor conference participations showing strong institutional interest
- CEO and management team engaging directly with investors through fireside chats and one-on-one meetings
- Company providing broad market access through live webcasts of presentations
Negative
- None.
NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company’s participation appear below:
Chardan Capital’s Trending Issues in Drug Development Conference – April 29, 2025 (Virtual)
David Hochman, Orchestra BioMed’s Chairman and Chief Executive Officer, will participate in a fireside chat with Keay Nakae, Senior Research Analyst, Chardan on the topic of “Data & Regulatory Catalysts – Navigating an Evolving Landscape,” which is scheduled for 10:30am ET on Tuesday, April 29. The virtual event will be accessible to investors and interested parties via a live webcast, which will be available live via this link, as well as after the event on Orchestra BioMed’s Investor Relations website.
Jefferies Global Healthcare Conference – June 5, 2025 (New York, NY)
Management will participate in a live fireside chat at 3:45pm ET on Thursday, June 5 and will also host one-on-one meetings with investors. The event will be accessible to investors and interested parties via a live webcast, which will be available live via this link, as well as after the event on Orchestra BioMed’s Investor Relations website.
Management will also deliver a live presentation at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20 and host one-on-one meetings with investors.
About Orchestra BioMed
Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy (formerly referred to as BackBeat Cardiac Neuromodulation Therapy (CNT™)) for the treatment of hypertension, the leading risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
References to Websites and Social Media Platforms
References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.
Investor Contact:
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
Kkirkellis@orchestrabiomed.com
FAQ
Which investor conferences will Orchestra BioMed (OBIO) attend in 2025?
When is Orchestra BioMed's (OBIO) presentation at the Chardan Capital conference?
How can investors watch Orchestra BioMed's (OBIO) conference presentations online?
What type of meetings will Orchestra BioMed (OBIO) hold at the Jefferies conference?
Where will Orchestra BioMed (OBIO) present at the H.C. Wainwright conference?
